En un meta-anlisis realizado de los principales ensayos clnicos publicados se evalu el perfil de seguridad cardiovascular de la lixisenatida (ELIXA), liraglutida (LEADER), semaglutida (SUSTAIN-6) y exenatida de liberacin prolongada (EXSCEL), siendo la mortalidad cardiovascular, el infarto al miocardio no fatal y el ictus no fatal las principales variables de resultado en los ltimos tres, mientras que en el estudio ELIXA se estudi adems como variable principal la hospitalizacin por angina inestable
Funding Open Access funding enabled and organized by Seoul National University
Mol Metab 46:101102
In this observational cohort study, we used the Maccabi Healthcare Services (MHS) database, Israel's second-largest healthcare maintenance organization (HMO), to compare kidney outcomes in patients with type 2 diabetes initiating GLP-1 RAs versus basal insulin
The labeled cystine was injected 6 h prior to tumor excision
If you want or need to stop taking Wegovy, talk to your healthcare provider first to make a plan for continuing to manage your weight and reduce your risk of cardiovascular disease